Valuation: 4D Molecular Therapeutics, Inc.

Market Cap 597M 534M 494M 447M 836M 56.76B 850M 5.94B 2.35B 29.69B 2.24B 2.19B 94.01B P/E 2026 *
-2.61x
P/E 2027 * -2.7x
Enterprise Value 401M 359M 332M 301M 563M 38.2B 572M 4B 1.58B 19.98B 1.51B 1.47B 63.26B EV / Sales 2026 *
30.3x
EV / Sales 2027 * 12.7x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: 4D Molecular Therapeutics, Inc.

1 day+2.13%
1 week-9.14%
Current month-22.92%
1 month-23.77%
3 months+9.53%
6 months+17.34%
Current year+47.07%
1 week 10.62
Extreme 10.62
13.45
1 month 10.62
Extreme 10.62
14.97
Current year 6.96
Extreme 6.96
16.93
1 year 6.96
Extreme 6.96
16.93
3 years 2.24
Extreme 2.235
36.25
5 years 2.24
Extreme 2.235
36.25
10 years 2.24
Extreme 2.235
55.11
Manager TitleAgeSince
Chief Operating Officer 51 01/04/2018
Chief Executive Officer 64 12/09/2013
Director of Finance/CFO 51 17/11/2025
Director TitleAgeSince
Chairman 64 12/09/2013
Director/Board Member 62 01/12/2015
Director/Board Member 47 01/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Founder

-58,333 0.1056%
16/09/26 Exercice

Compliance Officer

4,905 0.0089%
14/09/26 Sell

Founder

-58,333 0.1056%
Change 5-day change 1-year change 3-year change Capi.($)
+2.13%-9.14%-2.73%+6.36% 597M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+7.23%+11.14%+74.78% 54.78B
+0.47%+5.10%+8.22%+101.52% 53.49B
-2.06%+2.51%+24.07%+50.98% 45.98B
-1.79%+0.49%+19.32%+122.77% 42.94B
-1.65%+3.34%+237.56%+819.04% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+18.47%+55.14%+45.58% 23.67B
Average +0.78%+0.90%+43.53%+134.16% 38.37B
Weighted average by Cap. +0.12%+2.57%+45.85%+149.65%

Financials

2026 *2027 *
Net sales 13.26M 11.85M 10.97M 9.93M 18.58M 1.26B 18.89M 132M 52.2M 660M 49.75M 48.69M 2.09B 20.63M 18.45M 17.07M 15.46M 28.93M 1.96B 29.4M 205M 81.25M 1.03B 77.44M 75.79M 3.25B
Net income -289M -258M -239M -216M -405M -27.46B -411M -2.87B -1.14B -14.36B -1.08B -1.06B -45.47B -316M -283M -262M -237M -443M -30.09B -451M -3.15B -1.25B -15.74B -1.19B -1.16B -49.82B
Net Debt -195M -175M -161M -146M -274M -18.57B -278M -1.94B -768M -9.71B -732M -717M -30.75B -334M -299M -276M -250M -468M -31.79B -476M -3.33B -1.32B -16.62B -1.25B -1.23B -52.64B
Projected Income Statement - Annual - 4D Molecular Therapeutics, Inc.
Logo 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Employees
196
Date Price Change Volume
27/10/26 $11.03 +2.13% 1,084,577
23/10/26 $10.80 -8.86% 996,140
22/10/26 $11.85 -6.10% 1,354,686
21/10/26 $12.62 -3.66% 2,019,208
20/10/26 $13.10 +6.59% 725,371
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - 4D Molecular Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
10.80USD
Average target price
28.09USD
Spread / Average Target
+160.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - 4D Molecular Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FDMT Stock